3French G. Safety and tolerability of linezolid[J].Journal of Antimicrobial Chemotherapy,2003,(02):45-53.
4Green SL,Maddox JC,Huttenbach ED. Linezolid and reversible myelosuppression[J].Journal of the American Medical Association,2001,(10):1291.doi:10.1001/jama.285.10.1291.
5Skia J,Stefani KW. Linezolid-novel antibiotic for the treatment of Gram-positive bacterial infections[J].Wiadomosci Lekarskie,2006,(9/10):727-731.
6Boselli E. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator associated pneumonia[J].Critical Care Medicine,2005,(07):1529-1533.doi:10.1097/01.CCM.0000168206.59873.80.
7Conte JE Jr. lntrapulmonary pharnacokinetics of linezolid[J].Antimicrobial Agents and Chemotherapy,2002,(05):1475-1480.doi:10.1128/AAC.46.5.1475-1480.2002.
2Clinical and I.aboratory Standards Institute(CLSI). Perform ance standards for Antimicrobial susceptibility testing[S]. M100-S17, 2007.
3Clinical and Laboratory Standards Institute (CLSI). Perform anee standards for Antimicrobial susceptibility testing [S]. M100-S19,2009.
4Bratu S, I.andman D, Haag R, et al. Rapid spread of carbapenem resistant Klebsiella pneumoniae in New York City: anew threat to our antibiotic armamentarium[J]. Arch Int Meal.2005,165(12) :1430-1435.
5Endimiani A, Hujer AM, Perez F, et al. Characterization of blaKPC containing Klebsiella pneumoniae isolates detected in different institutions in the eastern USA [J]. J Antimierob Chemother, 2009, 63(3):427-437.
6Jeon BC, Jeong SH, Bae IK, et al. Investigation of a nosocomial outbreak of imipenem resistant Acinetobacter baumannii producing the OXA- 23 β- lactamase in Korea[J]. J Clin Microbiol, 2005, 43(5):2241 -2245.
7NaasT, LevyM, HirschauerC, et al. Outbreak ofcarbapen em resistant Acinetobacter baumannii producing the carbap enemase OXA- 23 in a tertiary care hospital of Pepcete, French Polynesta[J]. J Clin Mierohiol, 2005, 43 (9) : 4826- 4829.
8Waites KB, Dully LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and invitro activity of tigecycline, a new glycylcycline antimicrobial[J]. Antimicrob Agents Chemother, 2006,50(10):3479- 3484.
9Souli M, Kontopidou FV, Koratzanis E, et al. lnvitro activity of tigecycline against multiple-drug resistant, including pan resistant, Gram negative and Gram-positive clinical isolates from Greek hospitals[J]. Antimicrob Agents Chemother, 2006.50(9) :3166- 3169.
10Gordon NC, Warehan, DW. A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline [J]. J Antimicrob Chemother, 2009, 63(4) :775-780.
